Lipid-Lowering Drugs and Circulating Adiponectin

Vitamins and Hormones

Volumn 90, Issue , 2012, Pages 341-374

  Wanders, Desiree ^a   Plaisance, Eric P ^b   Judd, Robert L ^a  

^a AUBURN UNIVERSITY   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Adiponectin; Cardiovascular disease; Fibrates; Hyperlipidemia; Niacin; Omega 3 fatty acids; Statins

Indexed keywords

EID: 84866610505     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398313-8.00013-0     Document Type: Chapter

References (136)

1. Altschul R., Hoffer A., Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Archives of Biochemistry and Biophysics 1955, 54:558-559.
2. Anagnostis P., Selalmatzidou D., Polyzos S.A., Panagiotou A., Slavakis A., Panagiotidou A., et al. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: A prospective randomised open-label study. International Journal of Clinical Practice 2011, 65:679-683.
3. Anderlova K., Dolezalova R., Housova J., Bosanska L., Haluzikova D., Kremen J., et al. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiological Research 2007, 56:579-586.
4. Ando H., Sugimoto K., Yanagihara H., Tsuruoka S., Saito T., Takamura T., et al. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clinical and Experimental Pharmacology & Physiology 2008, 35:1012-1017.
5. Arita Y., Kihara S., Ouchi N., Maeda K., Kuriyama H., Okamoto Y., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002, 105:2893-2898.
6. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet 2005, 366:1267-1278.
7. Bayes B., Granada M.L., Lauzurica R., Pastor M.C., Navarro M., Bonet J., et al. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. Transplantation Proceedings 2005, 37:3808-3812.
8. Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 2001, 7:947-953.
9. Birjmohun R.S., Hutten B.A., Kastelein J.J., Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. Journal of the American College of Cardiology 2005, 45:185-197.
10. Blanco-Colio L.M., Martin-Ventura J.L., Gomez-Guerrero C., Masramon X., de T.E., Farsang C., et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. European Journal of Pharmacology 2008, 586:259-265.
11. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA: The Journal of the American Medical Association 1987, 257:3233-3240.
12. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England Journal of Medicine 1990, 323:1289-1298.
13. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. Journal of the American College of Cardiology 1986, 8:1245-1255.
14. Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Medica Scandinavica 1988, 223:405-418.
15. Chamberlain L.H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Letters 2001, 507:357-361.
16. Chinetti G., Zawadski C., Fruchart J.C., Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochemical and Biophysical Research Communications 2004, 314:151-158.
17. Choi K.C., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., Kim S.G., et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochemical and Biophysical Research Communications 2005, 336:747-753.
18. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. The Lancet 2004, 364:685-696.
19. Combs T.P., Berg A.H., Obici S., Scherer P.E., Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. The Journal of Clinical Investigation 2001, 108:1875-1881.
20. Combs T.P., Wagner J.A., Berger J., Doebber T., Wang W.J., Zhang B.B., et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: A potential mechanism of insulin sensitization. Endocrinology 2002, 143:998-1007.
21. Deng G., Long Y., Yu Y.R., Li M.R. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. International Journal of Obesity 2010, 34:165-171.
22. Devaraj S., Siegel D., Jialal I. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. The American Journal of Cardiology 2007, 100:1397-1399.
23. Digby J.E., McNeill E., Dyar O.J., Lam V., Greaves D.R., Choudhury R.P. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 2010, 209:89-95.
24. Dipalma J.R., Thayer W.S. Use of niacin as a drug. Annual Review of Nutrition 1991, 11:169-187.
25. Dolgin E. Trial puts niacin-and cholesterol dogma-in the line of fire. Nature Medicine 2011, 17:756.
26. Duda M.K., O'Shea K.M., Lei B., Barrows B.R., Azimzadeh A.M., McElfresh T.E., et al. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovascular Research 2007, 76:303-310.
27. Flachs P., Mohamed-Ali V., Horakova O., Rossmeisl M., Hosseinzadeh-Attar M.J., Hensler M., et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006, 49:394-397.
28. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:4312-4317.
29. Forst T., Pfutzner A., Lubben G., Weber M., Marx N., Karagiannis E., et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT study. Metabolism 2007, 56:491-496.
30. Freeman D.J., Norrie J., Sattar N., Neely R.D., Cobbe S.M., Ford I., et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
31. Gannage-Yared M.H., Azar R.R., Amm-Azar M., Khalife S., Germanos-Haddad M., Neemtallah R., et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005, 54:947-951.
32. Goldberg A.C. Clinical trial experience with extended-release niacin (Niaspan): Dose-escalation study. The American Journal of Cardiology 1998, 82:35U-38U.
33. Gotto A.M. Triglyceride as a risk factor for coronary artery disease. The American Journal of Cardiology 1998, 82:22Q-25Q.
34. Gould A.L., Rossouw J.E., Santanello N.C., Heyse J.F., Furberg C.D. Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 1998, 97:946-952.
35. Grundy S.M. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997, 95:1-4.
36. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends in Pharmacological Sciences 1998, 19:26-37.
37. Harris W.S. n-3 fatty acids and serum lipoproteins: Human studies. The American Journal of Clinical Nutrition 1997, 65:1645S-1654S.
38. Hiuge A., Tenenbaum A., Maeda N., Benderly M., Kumada M., Fisman E.Z., et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:635-641.
39. Hotta K., Funahashi T., Bodkin N.L., Ortmeyer H.K., Arita Y., Hansen B.C., et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001, 50:1126-1133.
40. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. The Journal of Biological Chemistry 1996, 271:10697-10703.
41. Hu F.B., Bronner L., Willett W.C., Stampfer M.J., Rexrode K.M., Albert C.M., et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA: The Journal of the American Medical Association 2002, 287:1815-1821.
42. Itoh M., Suganami T., Satoh N., Tanimoto-Koyama K., Yuan X., Tanaka M., et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:1918-1925.
43. Jackevicius C.A., Tu J.V., Ross J.S., Ko D.T., Carreon D., Krumholz H.M. Use of fibrates in the United States and Canada. JAMA: The Journal of the American Medical Association 2011, 305:1217-1224.
44. Jun M., Foote C., Lv J., Neal B., Patel A., Nicholls S.J., et al. Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis. The Lancet 2010, 375:1875-1884.
45. Kanda M., Satoh K., Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biological & Pharmaceutical Bulletin 2003, 26:1681-1684.
46. Khan T., Hamilton M.P., Mundy D.I., Chua S.C., Scherer P.E. Impact of simvastatin on adipose tissue: Pleiotropic effects in vivo. Endocrinology 2009, 150:5262-5272.
47. Kissebah A.H., Adams P.W., Harrigan P., Wynn V. The mechanism of action of clofibrate and tetranicotinoylfructose (Bradilan) on the kinetics of plasma free fatty acid and triglyceride transport in type IV and type V hypertriglyceridaemia. European Journal of Clinical Investigation 1974, 4:163-174.
48. Kleinman Y., Eisenberg S., Oschry Y., Gavish D., Stein O., Stein Y. Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. Normalization with bezafibrate therapy. The Journal of Clinical Investigation 1985, 75:1796-1803.
49. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:4318-4323.
50. Knopp R.H., Alagona P., Davidson M., Goldberg A.C., Kafonek S.D., Kashyap M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097-1104.
51. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687-3692.
52. Koh K.K., Han S.H., Quon M.J., Yeal A.J., Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419-1424.
53. Koh K.K., Quon M.J., Han S.H., Ahn J.Y., Jin D.K., Kim H.S., et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005, 45:1088-1093.
54. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. Journal of the American College of Cardiology 2005, 45:1649-1653.
55. Koh K.K., Quon M.J., Han S.H., Lee Y., Ahn J.Y., Kim S.J., et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008, 31:776-782.
56. Koh K.K., Quon M.J., Han S.H., Lee Y., Kim S.J., Park J.B., et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009, 204:483-490.
57. Koh K.K., Quon M.J., Han S.H., Lee Y., Kim S.J., Shin E.K. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. Journal of the American College of Cardiology 2010, 55:1209-1216.
58. Koh K.K., Quon M.J., Han S.H., Lee Y., Park J.B., Kim S.J., et al. Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. International Journal of Cardiology 2011, 146:319-325.
59. Koh K.K., Quon M.J., Lim S., Lee Y., Sakuma I., Lee Y.H., et al. Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. Atherosclerosis 2011, 214:144-147.
60. Koh K.K., Quon M.J., Sakuma I., Lee Y., Lim S., Han S.H., et al. Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia. International Journal of Cardiology 2011, 146:434-437.
61. Koh K.K., Sakuma I., Quon M.J. Differential metabolic effects of distinct statins. Atherosclerosis 2011, 215:1-8.
62. Kondo K., Morino K., Nishio Y., Kondo M., Fuke T., Ugi S., et al. Effects of a fish-based diet on the serum adiponectin concentration in young, non-obese, healthy Japanese subjects. Journal of Atherosclerosis and Thrombosis 2010, 17:628-637.
63. Kratz M., Swarbrick M.M., Callahan H.S., Matthys C.C., Havel P.J., Weigle D.S. Effect of dietary n-3 polyunsaturated fatty acids on plasma total and high-molecular-weight adiponectin concentrations in overweight to moderately obese men and women. The American Journal of Clinical Nutrition 2008, 87:347-353.
64. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Molecular Endocrinology 1997, 11:779-791.
65. Krysiak R., Labuzek K., Okopien B. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacological Reports 2009, 61:1134-1145.
66. Kubota N., Yano W., Kubota T., Yamauchi T., Itoh S., Kumagai H., et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metabolism 2007, 6:55-68.
67. Li P., Shibata R., Maruyama S., Kondo M., Ohashi K., Ouchi N., et al. Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway. American Journal of Physiology. Endocrinology and Metabolism 2010, 299:E560-E566.
68. Linke A., Sonnabend M., Fasshauer M., Hollriegel R., Schuler G., Niebauer J., et al. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis 2009, 205:207-213.
69. Lithell H., Boberg J., Hellsing K., Lundqvist G., Vessby B. Increase of the lipoprotein-lipase activity in human skeletal muscle during clofibrate administration. European Journal of Clinical Investigation 1978, 8:67-74.
70. Lorente-Cebrian S., Perez-Matute P., Martinez J.A., Marti A., Moreno-Aliaga M.J. Effects of eicosapentaenoic acid (EPA) on adiponectin gene expression and secretion in primary cultured rat adipocytes. Journal of Physiology and Biochemistry 2006, 62:61-69.
71. Ma J., Sehgal N.L., Ayanian J.Z., Stafford R.S. National trends in statin use by coronary heart disease risk category. PLoS Medicine 2005, 2:e123.
72. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Medicine 2002, 8:731-737.
73. Maragoudakis M.E. On the mode of action of lipid-lowering agents. II. in vitro inhibition of acetyl coenzyme A carboxylase by a hypolipidemic drug. Biochemistry 1970, 9:413-417.
74. Matafome P., Louro T., Rodrigues L., Crisostomo J., Nunes E., Amaral C., et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes/Metabolism Research and Reviews 2011, 27:54-62.
75. Miyagishima K., Hiramitsu S., Kato S., Kato Y., Kitagawa F., Teradaira R., et al. Efficacy of atorvastatin therapy in ischaemic heart disease-Effects on oxidized low-density lipoprotein and adiponectin. The Journal of International Medical Research 2007, 35:534-539.
76. Mori T.A., Beilin L.J. Omega-3 fatty acids and inflammation. Current Atherosclerosis Reports 2004, 6:461-467.
77. Mori Y., Oana F., Matsuzawa A., Akahane S., Tajima N. Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: A study in spontaneously type 2 diabetic rats with visceral obesity. Endocrine 2004, 25:247-251.
78. Naderali E.K., Fatani S., Telles M., Hunter L. The effects of physiological and pharmacological weight loss on adiponectin and leptin mRNA levels in the rat epididymal adipose tissue. European Journal of Pharmacology 2008, 579:433-438.
79. Nakamura T., Kodama Y., Takano H., Umetani K., Fujioka D., Saito Y., et al. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 2007, 193:449-451.
80. Nakano S., Inada Y., Masuzaki H., Tanaka T., Yasue S., Ishii T., et al. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. American Journal of Physiology. Endocrinology and Metabolism 2007, 292:E1213-E1222.
81. Nawrocki A.R., Rajala M.W., Tomas E., Pajvani U.B., Saha A.K., Trumbauer M.E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. The Journal of Biological Chemistry 2006, 281:2654-2660.
82. Neschen S., Morino K., Rossbacher J.C., Pongratz R.L., Cline G.W., Sono S., et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 2006, 55:924-928.
83. Nomura S., Inami N., Shouzu A., Omoto S., Kimura Y., Takahashi N., et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 2009, 20:16-22.
84. Nomura S., Shouzu A., Omoto S., Inami N., Shimazu T., Satoh D., et al. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients. Blood Coagulation & Fibrinolysis 2009, 20:440-447.
85. Oki K., Koide J., Nakanishi S., Nakashima R., Yamane K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocrine Journal 2007, 54:431-435.
86. Otto C., Otto B., Frost R.J., Vogeser M., Pfeiffer A.F., Spranger J., et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetologica 2007, 44:65-68.
87. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
88. Palmer R.H. Effects of fibric acid derivatives on biliary lipid composition. The American Journal of Medicine 1987, 83:37-43.
89. Perez-Matute P., Perez-Echarri N., Martinez J.A., Marti A., Moreno-Aliaga M.J. Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: Role of apoptosis, adiponectin and tumour necrosis factor-alpha. The British Journal of Nutrition 2007, 97:389-398.
90. Pfutzner A., Schondorf T., Hanefeld M., Lubben G., Kann P.H., Karagiannis E., et al. Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients. Hormone and Metabolic Research 2009, 41:202-206.
91. Plaisance E.P., Grandjean P.W., Brunson B.L., Judd R.L. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism 2008, 57:404-409.
92. Plaisance E.P., Grandjean P.W., Mahurin A.J. Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: A qualitative review. The Physician and Sportsmedicine 2009, 37:11-19.
93. Plaisance E.P., Lukasova M., Offermanns S., Zhang Y., Cao G., Judd R.L. Niacin stimulates adiponectin secretion through the GPR109A receptor. American Journal of Physiology. Endocrinology and Metabolism 2009, 296:E549-E558.
94. Qi Y., Takahashi N., Hileman S.M., Patel H.R., Berg A.H., Pajvani U.B., et al. Adiponectin acts in the brain to decrease body weight. Nature Medicine 2004, 10:524-529.
95. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., et al. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 2011, 123:e18-e209.
96. Rosenson R.S. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring) 2009, 17:504-509.
97. Rossi A.S., Lombardo Y.B., Lacorte J.M., Chicco A.G., Rouault C., Slama G., et al. Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin-resistant rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2005, 289:R486-R494.
98. Sakamoto K., Sakamoto T., Ogawa H. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: A pilot study. Clinical Therapeutics 2006, 28:1012-1021.
99. Saraswathi V., Gao L., Morrow J.D., Chait A., Niswender K.D., Hasty A.H. Fish oil increases cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in mice. The Journal of Nutrition 2007, 137:1776-1782.
100. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. The Journal of Biological Chemistry 1995, 270:26746-26749.
101. Serajuddin A.T., Ranadive S.A., Mahoney E.M. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. Journal of Pharmaceutical Sciences 1991, 80:830-834.
102. Shepherd J. Mechanism of action of fibrates. Postgraduate Medical Journal 1993, 69(Suppl. 1):S34-S41.
103. Shetty G.K., Economides P.A., Horton E.S., Mantzoros C.S., Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004, 27:2450-2457.
104. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.
105. Sneddon A.A., Tsofliou F., Fyfe C.L., Matheson I., Jackson D.M., Horgan G., et al. Effect of a conjugated linoleic acid and omega-3 fatty acid mixture on body composition and adiponectin. Obesity (Silver Spring) 2008, 16:1019-1024.
106. Sonmez A., Dogru T., Tasci I., Yilmaz M.I., Pinar M., Naharci I., et al. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia. Clinical Endocrinology 2006, 64:567-572.
107. Suganami T., Nishida J., Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: Role of free fatty acids and tumor necrosis factor alpha. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25:2062-2068.
108. Sugiyama S., Fukushima H., Kugiyama K., Maruyoshi H., Kojima S., Funahashi T., et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007, 194:e43-e51.
109. Takagi T., Matsuda M., Abe M., Kobayashi H., Fukuhara A., Komuro R., et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008, 196:114-121.
110. Tenenbaum A., Motro M., Fisman E.Z., Schwammenthal E., Adler Y., Goldenberg I., et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109:2197-2202.
111. The Coronary Drug Project Findings leading to discontinuation of the 2.5-mg day estrogen group. The Coronary Drug Project Research Group. JAMA: The Journal of the American Medical Association 1973, 226:652-657.
112. Thongtang N., Ai M., Otokozawa S., Himbergen T.V., Asztalos B.F., Nakajima K., et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. The American Journal of Cardiology 2011, 107:387-392.
113. Trujillo M.E., Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. Journal of Internal Medicine 2005, 257:167-175.
114. Vega G.L., Ma P.T., Cater N.B., Filipchuk N., Meguro S., Garcia-Garcia A.B., et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. The American Journal of Cardiology 2003, 91:956-960.
115. Viollet B., Guigas B., Leclerc J., Hebrard S., Lantier L., Mounier R., et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: From physiology to therapeutic perspectives. Acta Physiologica (Oxford, England) 2009, 196:81-98.
116. von S.C., Harris W.S. Cardiovascular benefits of omega-3 fatty acids. Cardiovascular Research 2007, 73:310-315.
117. von E.M., Schneider J.G., Hadziselimovic S., Hamann A., Bierhaus A., Nawroth P.P., et al. Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care 2005, 28:754-755.
118. von E.M., Liu D., Bluemm A., Schuster T., Baumann M., Lutz J., et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clinical Endocrinology 2009, 71:27-32.
119. Walldius G., Wahlberg G. Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis. Advances in Experimental Medicine and Biology 1985, 183:281-293.
120. Wang Z.V., Schraw T.D., Kim J.Y., Khan T., Rajala M.W., Follenzi A., et al. Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Molecular and Cellular Biology 2007, 27:3716-3731.
121. Westphal S., Luley C. Preferential increase in high-molecular weight adiponectin after niacin. Atherosclerosis 2008, 198:179-183.
122. Westphal S., Borucki K., Taneva E., Makarova R., Luley C. Adipokines and treatment with niacin. Metabolism 2006, 55:1283-1285.
123. Westphal S., Borucki K., Taneva E., Makarova R., Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007, 193:361-365.
124. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: From orphan receptors to drug discovery. Journal of Medicinal Chemistry 2000, 43:527-550.
125. Wu H., Wei L., Bao Y., Lu J., Huang P., Liu Y., et al. Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. American Journal of Physiology. Endocrinology and Metabolism 2009, 296:E628-E634.
126. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. The Journal of Clinical Investigation 2003, 112:91-100.
127. 2+ channels in rat islet beta-cells. British Journal of Pharmacology 1999, 126:1205-1213.
128. Yamamoto K., Itoh T., Abe D., Shimizu M., Kanda T., Koyama T., et al. Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. Bioorganic & Medicinal Chemistry Letters 2005, 15:517-522.
129. Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. The Journal of Biological Chemistry 2001, 276:41245-41254.
130. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001, 7:941-946.
131. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 2002, 8:1288-1295.
132. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nature Medicine 2007, 13:332-339.
133. Yang W.S., Jeng C.Y., Wu T.J., Tanaka S., Funahashi T., Matsuzawa Y., et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002, 25:376-380.
134. Yano M., Matsumura T., Senokuchi T., Ishii N., Murata Y., Taketa K., et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circulation Research 2007, 100:1442-1451.
135. Yin X., Tu L., Yang H. Effect of simvastatin on IL-6 and adiponectin secretion and mRNA expression in 3T3-L1 adipocytes. Journal of Huazhong University of Science and Technology. Medical Sciences 2007, 27:248-251.
136. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. The Lancet 2007, 369:1090-1098.